🟢 Moderna is trading 4.3% up in pre-market after Fed’s September 16 rate decision

Moderna is trading 4.32% up at $151.91 after a firm broader-market recovery following the Federal Reserve’s September 16 rate decision.

• Major U.S. indices are also higher pre-market, supporting risk appetite across growth and healthcare stocks.
• No new company-specific announcement clearly explains the September 17 move.
• Moderna’s September 14 Morgan Stanley presentation highlighted oncology progress and retained 2028 break-even guidance, but coverage does not explicitly link those disclosures to current price action.